JAK1 Inhibitor Zemprocitinib Hits Targets in Refractory RA

by admin | Jun 6, 2026 | Health

Spread the love

Zemprocitinib, a next-generation JAK1 inhibitor, may tame rheumatoid arthritis that does not respond to at least one biologic disease-modifying antirheumatic drug, a phase 3 clinical trial finds.
Medscape Medical News

← South Korean protesters keep calling for re-run of election after ballot shortage Petrelintide Tolerability Could Improve on GLP-1 Challenges →

Written By

Written by Albert Pham, News Curator and Blogger

Cocaine Trade Booms Despite U.S. Airstrikes and Drug Crackdown

Oct 13, 2026 | albertpham, Economy_finances, Health

The global cocaine trade continues to expand despite U.S. airstrikes against suspected smugglers. Discover why trafficking networks remain resilient.

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Oct 12, 2026 | albertpham, Economy_finances, Health

McDonald’s is expanding its chicken menu and specialty beverages to gain market share by 2030, challenge competitors and attract more customers.

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

Oct 12, 2026 | albertpham, Health, Travel

Canadian women are travelling to Mexico for endometriosis treatment after facing long wait times, highlighting gaps in specialist care and women’s health services.

JAK1 Inhibitor Zemprocitinib Hits Targets in Refractory RA

Written By

Related Posts

Cocaine Trade Booms Despite U.S. Airstrikes and Drug Crackdown

McDonald’s Chicken and Beverage Strategy: Global Growth Plans Through 2030

Endometriosis in Canada: Why Women Are Seeking Treatment in Mexico

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated